2026/08/06 by Kanade Iino, Saori Takamura, Tomoo Fukuda
paper · doi:10.1111/1346-8138.70448
crossref issued 2026/08/06 · crossref published 2026/08/06 · crossref published-online 2026/08/06 · crossref created 2026/08/07 · crossref deposited 2026/08/07 · crossref indexed 2026/08/07
ABSTRACT Background Tapinarof cream 1%, a non‐steroidal topical aryl hydrocarbon receptor‐modulating agent, is approved in Japan for atopic dermatitis (AD) and plaque psoriasis. Real‐world data on longitudinal outcomes, treatment continuation, interruption and restart, and adverse‐event timing are limited. Methods This single‐center retrospective study included patients newly prescribed tapinarof cream 1% from November 2024 to July 24, 2025. The full analysis set comprised 37 AD and 58 plaque psoriasis patients. Primary endpoints were Eczema Area and Severity Index 50% improvement (EASI50) at week 8 for AD and Psoriasis Area and Severity Index 75% improvement (PASI75) at week 12 for psoriasis. Observed‐case and non‐responder imputation (NRI) analyses were reported. Results In AD, week‐8 EASI50 was achieved by 12/24 evaluable patients (50.0%) and 12/37 under NRI (32.4%). Mean EASI decreased from 5.94 at baseline to 2.56 at week 8 and 0.83 at week 52. Week‐52 EASI was available for 13/37 overall (13/27 with ascertainable status at the data cutoff). In psoriasis, week‐12 PASI75 was achieved by 15/33 evaluable patients (45.5%) and 15/58 under NRI (25.9%). Mean PASI decreased from 2.95 at baseline to 1.18 at week 12 and 0.43 at week 52. Week‐52 PASI was available for 25/58 overall (25/49 with ascertainable status at the data cutoff); long‐term summaries were observed‐case and potentially responder‐enriched. Any adverse event was recorded in 11/37 AD patients and 12/58 psoriasis patients. Median headache onset was 8 h in AD and 1.8 days in psoriasis. No serious drug‐related adverse event was recorded. No pigmentary change was documented; however, without standardized colorimetry or photography, its absence cannot be confirmed. Conclusion Tapinarof‐containing treatment was associated with clinically meaningful improvement in AD and plaque psoriasis in routine practice, although frequent concomitant therapy, observed‐case long‐term analyses, and retrospective ascertainment limit causal and safety inferences.